244 related articles for article (PubMed ID: 35928877)
1. Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review.
Zhang Y; Xing Z; Mi L; Li Z; Zhu J; Wei T; Wu W
Front Oncol; 2022; 12():929012. PubMed ID: 35928877
[TBL] [Abstract][Full Text] [Related]
2. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.
Vassilakopoulos TP; Asimakopoulos JV; Konstantopoulos K; Angelopoulou MK
Ther Adv Hematol; 2020; 11():2040620720902911. PubMed ID: 32110285
[TBL] [Abstract][Full Text] [Related]
3. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
5. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
6. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
7. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Choi Y; Diefenbach CS
Curr Oncol Rep; 2020 Jan; 22(1):6. PubMed ID: 31981025
[TBL] [Abstract][Full Text] [Related]
8. A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma.
Raut M; Singh G; Hiscock I; Sharma S; Pilkhwal N
Expert Rev Hematol; 2022 Jul; 15(7):607-617. PubMed ID: 35794714
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.
Randall MP; Spinner MA
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760478
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation.
Domingo-Domènech E; Sureda A
J Clin Med; 2020 May; 9(5):. PubMed ID: 32397141
[TBL] [Abstract][Full Text] [Related]
12. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Song Y; Guo Y; Huang H; Li W; Ke X; Feng J; Xu W; Miao H; Kinley J; Song G; Dai Y; Wang H; Zhu J
Expert Rev Hematol; 2021 Sep; 14(9):867-875. PubMed ID: 34275403
[TBL] [Abstract][Full Text] [Related]
13. Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era.
Abuelgasim KA; Ghazi S; Alahmari B; Alhejazi A; Alaskar A; Alzahrani M; Damlaj M
Leuk Res Rep; 2021; 16():100276. PubMed ID: 34804792
[TBL] [Abstract][Full Text] [Related]
14. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies.
Vassilakopoulos TP; Chatzidimitriou C; Asimakopoulos JV; Arapaki M; Tzoras E; Angelopoulou MK; Konstantopoulos K
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31362369
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
18. Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches.
Hanel W; Herrera AF; Epperla N
Exp Hematol Oncol; 2022 Dec; 11(1):108. PubMed ID: 36575540
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.
Tarekegn K; Colon Ramos A; Singh B; Sequeira Gross HG; Gupta S
World J Oncol; 2021 Aug; 12(4):81-84. PubMed ID: 34349851
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]